{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:12:44Z","timestamp":1777475564794,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00774-020-01151-9","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T12:03:01Z","timestamp":1599220981000},"page":"295-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents"],"prefix":"10.1007","volume":"39","author":[{"given":"Yasutomo","family":"Nakai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kanaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinaru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nagahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Kakimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-1350","authenticated-orcid":false,"given":"Kazuo","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"1151_CR1","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0022-5347(05)00999-7","volume":"175","author":"J Morote","year":"2006","unstructured":"Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2006) Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol 175:1679\u20131683","journal-title":"J Urol"},{"key":"1151_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154\u2013164","journal-title":"N Engl J Med"},{"key":"1151_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2013.36","volume":"9","author":"RE Coleman","year":"2013","unstructured":"Coleman RE, Rathbone E, Brown JE (2013) Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 9:365\u2013374","journal-title":"Nat Rev Rheumatol"},{"key":"1151_CR4","unstructured":"National Comprehensive Cancer Network (2019) NCCN Clinical Practice Guidelines in Oncology Prostate Cancer version 4."},{"key":"1151_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M (2015) Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol 68:325\u2013334","journal-title":"Eur Urol"},{"key":"1151_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","volume":"65","author":"C Pezaro","year":"2014","unstructured":"Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, Bianchini D, Mukherji D, Riisnaes R, Altavilla A, Crespo M, Tunariu N, de Bono J, Attard G (2014) Visceral disease in castration-resistant prostate cancer. Eur Urol 65:270\u2013273","journal-title":"Eur Urol"},{"key":"1151_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1442-2042.2010.02468.x","volume":"17","author":"A Yokomizo","year":"2010","unstructured":"Yokomizo A, Koga H, Shinohara N, Miyahara T, Machida N, Tsukino H, Uozumi J, Nishiyama K, Satoh F, Sakai H, Naito S (2010) Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan. Int J Urol 17:332\u2013336","journal-title":"Int J Urol"},{"key":"1151_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879\u2013882","journal-title":"J Natl Cancer Inst"},{"key":"1151_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"key":"1151_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","volume":"28","author":"T Yoneda","year":"2010","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365\u2013383","journal-title":"J Bone Miner Metab"},{"key":"1151_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"T Mavrokokki","year":"2007","unstructured":"Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415\u2013423","journal-title":"J Oral Maxillofac Surg"},{"key":"1151_CR12","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.joms.2018.04.009","volume":"76","author":"T Shibahara","year":"2018","unstructured":"Shibahara T, Morikawa T, Yago K, Kishimoto H, Imai Y, Kurita K (2018) National survey on bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 76:2105\u20132112","journal-title":"J Oral Maxillofac Surg"},{"key":"1151_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.oooo.2018.02.010","volume":"125","author":"T Higuchi","year":"2018","unstructured":"Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, Sasaki A (2018) Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 125:547\u2013551","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1151_CR14","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F, American Association of Oral, and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"1151_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.job.2019.03.005","volume":"61","author":"S Kuroshima","year":"2019","unstructured":"Kuroshima S, Sasaki M, Sawase T (2019) Medication-related osteonecrosis of the jaw: a literature review. J Oral Biosci 61:99\u2013104","journal-title":"J Oral Biosci"},{"key":"1151_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"key":"1151_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","volume":"48","author":"KH Taylor","year":"2010","unstructured":"Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 48:221\u2013223","journal-title":"Br J Oral Maxillofac Surg"},{"key":"1151_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","volume":"142","author":"JW Hellstein","year":"2011","unstructured":"Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H, American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 142:1243\u20131251","journal-title":"J Am Dent Assoc"},{"key":"1151_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1620\/tjem.247.75","volume":"247","author":"T Shibahara","year":"2019","unstructured":"Shibahara T (2019) Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med 247:75\u201386","journal-title":"Tohoku J Exp Med"},{"key":"1151_CR20","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Th\u00e9odore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512","journal-title":"N Engl J Med"},{"key":"1151_CR21","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513\u20131520","journal-title":"N Engl J Med"},{"key":"1151_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737\u2013746","journal-title":"N Engl J Med"},{"key":"1151_CR23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS De Bono","year":"2010","unstructured":"De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, Investigators TROPIC (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376:1147\u20131154","journal-title":"Lancet"},{"key":"1151_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39\u201346","journal-title":"Lancet"},{"key":"1151_CR25","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"1151_CR26","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092","journal-title":"Eur J Cancer"},{"key":"1151_CR27","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.jcms.2017.09.015","volume":"45","author":"N Heim","year":"2017","unstructured":"Heim N, Warwas FB, Wilms CT, Reich RH, Martini M (2017) Vitamin D (25\u20130HD) deficiency may increase the prevalence of medication-related osteonecrosis of the jaw. J Craniomaxillofac Surg 45:2068\u20132074","journal-title":"J Craniomaxillofac Surg"},{"key":"1151_CR28","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/jbmr.23","volume":"25","author":"A Hokugo","year":"2010","unstructured":"Hokugo A, Christensen R, Chung EM, Sung EC, Felsenfeld AL, Sayre JW, Garrett N, Adams JS, Nishimura I (2010) Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 25:1337\u20131349","journal-title":"J Bone Miner Res"},{"key":"1151_CR29","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1128\/IAI.00353-08","volume":"76","author":"JH White","year":"2008","unstructured":"White JH (2008) Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun 76:3837\u20133843","journal-title":"Infect Immun"},{"key":"1151_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","volume":"20","author":"AA Khan","year":"2017","unstructured":"Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA et al (2017) Case-based review of osteonecrosis of the jaw (ONJ) and application of the International Recommendation for Management from the International Task Force on ONJ. J Clin Densitom 20:8\u201324","journal-title":"J Clin Densitom"},{"key":"1151_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S (2017) Japanese Allied Committee on Osteonecrosis of the Jaw (2017) Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the jaw. J Bone Miner Metab 35:6\u201319","journal-title":"J Bone Miner Metab"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-020-01151-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-020-01151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T02:06:56Z","timestamp":1630721216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-020-01151-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1007\/s00774-020-01151-9","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"1 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical Standards"}},{"value":"K.N. received speaker honoraria from Astellas and Novartis; consulting fee from Astellas, AstraZeneca and Janssen; research funding from Bayer outside the submitted work. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}